Indivior

Indivior
Public company
Traded as LSE: INDV
Industry pharmaceuticals
Founded 1994
Headquarters Richmond, Virginia
Key people
 Howard Pien, Chairman
Shaun Thaxter, CEO
Products Subutex/Subuxone
Revenue $1,093 million (2017)[1]
$193 million (2017)[1]
$58 million (2017)[1]
Number of employees
 1,012 (2017)[1]
Website www.indivior.com/

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]

Operations

The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[5]

References

  1. 1 2 3 4 "Annual Report 2017" (PDF). Indivior. Retrieved 26 March 2018.
  2. 1 2 "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. ↑ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. ↑ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
  5. ↑ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.